SillaJen is strong in the NextTrade aftermarket (3:40 p.m. to 8 p.m.) on the 21st.
According to NextTrade that day, as of 7:22 p.m., SillaJen was trading at 3,005 won, up 615 won (25.73%) from the previous trading day. SillaJen finished at 2,440 won, up 2.09% from the prior trading day on the Korea Exchange.
SillaJen also announced that it received approval from the U.S. Food and Drug Administration (FDA) for a clinical trial protocol amendment to expand clinical trials of the anticancer drug BAL0891 for patients with acute myeloid leukemia (AML) just before the market close that day.
It also noted that it has decided to acquire the material patent and biomarker patent rights for BAL0891 from the Dutch biotech company Crossfire Oncology Holding B.V. The contract amount is 2 million Swiss francs (approximately 350 million won).